Search Results | Blood | American Society of Hematology

1-20 of 51

2 3

Sort by

Sort Order Select

Journal Articles

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Sravya Tumuluru, James Godfrey, Jovian Yu, Alan Cooper, Xiufen Chen, Gerben Duns, Sonali M. Smith, Christian Steidl, Justin Kline

Blood (2021) 138 (Supplement 1): 449.

DOI: https://doi.org/10.1182/blood-2021-153724

Published: 2021

Journal Articles

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Kirk Cahill, Michael Leukam, Theodore G. Karrison, Jessica Robertson, Justin Kline, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 2420.

DOI: https://doi.org/10.1182/blood-2021-152126

Published: 2021

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

DOI: https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Jovian Yu, MD, Xiufen Chen, PhD, James Godfrey, MD, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Mengjie Chen, PhD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40–41.

DOI: https://doi.org/10.1182/blood-2020-137171

Published: 2020

Journal Articles

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Ajay Major, MDMBA, Justin Kline, MD, Theodore G. Karrison, PhD, Paul A S Fishkin, MD, Amy S Kimball, MD PhD, Adam M Petrich, MD, Sreenivasa Nattam, MD, Bethany G Sleckman, MD, Kenneth Cohen, MD, Koen van Besien, MD PhD, Aaron P. Rapoport, MD, Sonali M. Smith, MD

Blood (2020) 136 (Supplement 1): 43–44.

DOI: https://doi.org/10.1182/blood-2020-134750

Published: 2020

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

DOI: https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Justin Kline, James Godfrey, Stephen M. Ansell

Blood (2020) 135 (8): 523–533.

DOI: https://doi.org/10.1182/blood.2019000847

Published: 2020

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

DOI: https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

DOI: https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

DOI: https://doi.org/10.1182/blood-2019-131562

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

DOI: https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Nicole Sunseri, MD PhD, Xiufen Chen, PhD, Noemie Wald, PhD, Julie Preillon, PhD, Sonali M. Smith, MD, Gregory Driessens, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 391.

DOI: https://doi.org/10.1182/blood-2019-131493

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

DOI: https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W. MacNabb, Robert Orlowski, Sonali M. Smith, Justin Kline

Blood (2019) 133 (21): 2279–2290.

DOI: https://doi.org/10.1182/blood-2018-10-879015

Published: 2019

Includes: Supplemental data

Journal Articles

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Justin Kline, MD, Hongtao Liu, MD PhD, Tallarico Michael, MD, Andrew S Artz, MD, James Godfrey, MD, Emily K Curran, MD, Wendy Stock, MD, Sonali M. Smith, MD, Michael R. Bishop, MD

Blood (2018) 132 (Supplement 1): 3415.

DOI: https://doi.org/10.1182/blood-2018-99-115108

Published: 2018

Journal Articles

Development of Acute Myeloid Leukemia Cell Membrane Coated Nanoparticles (AMCNPs) for Cancer Vaccination Immunotherapy

Daniel T Johnson, Ashley V Kroll, BS, Ronnie H Fang, PhD, Justin Kline, MD, Liangfang Zhang, PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 4062.

DOI: https://doi.org/10.1182/blood-2018-99-117841

Published: 2018

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Alison J. Moskowitz, MD, Armando Santoro, MD, Giuseppe Gritti, Pauline Brice, MD, David Cunningham, Paul Barr, MD, Justin Kline, MD, John Kuruvilla, MD, Nathalie A Johnson, MDPhD, Neha Mehta-Shah, MD, Thomas Manley, MD, Manish Sharma, Stephen Francis, Joseph Cohen, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 1691.

DOI: https://doi.org/10.1182/blood-2018-99-112069

Published: 2018

Journal Articles

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

Blood (2018) 132 (Supplement 1): 92.

DOI: https://doi.org/10.1182/blood-2018-99-117199

Published: 2018

Journal Articles

PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype

Justin Kline, MD, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Robert J Orlowski, MD, Sonali M. Smith, MD, Riyue Bao, PhD

Blood (2018) 132 (Supplement 1): 673.

DOI: https://doi.org/10.1182/blood-2018-99-117189

Published: 2018

2 3

NARROW

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Development of Acute Myeloid Leukemia Cell Membrane Coated Nanoparticles (AMCNPs) for Cancer Vaccination Immunotherapy

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only